Spero Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Spero Therapeutics, Inc. (SPRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.26 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 140.00K shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.12M shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 0.00 shares.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 35.60K shares, a 23.29% decline from fiscal 2023.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 46.41K shares, a 95.15% decline from fiscal 2022.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 956.60K shares, a 44.02% decline from fiscal 2021.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 1.71M shares, a 40.69% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 140.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 1.26M shares 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | 1.12M shares 10-Q · filed 2026-05-13 | |||
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-13 | 0.00 shares derived: sum of 2 quarters · filed 2025-05-13 | 0.00 shares derived: sum of 3 quarters · filed 2025-05-13 | 0.00 shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-27 | 0.00 shares derived: sum of 3 quarters · filed 2025-03-27 | 35.60K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-14 | 35.60K shares 10-Q · filed 2024-11-14 | 35.60K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 35.60K shares 10-Q · filed 2024-08-05 | 35.60K shares derived: sum of 3 quarters · filed 2024-08-05 | 35.60K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 35.60K shares 10-Q · filed 2024-05-15 | 35.60K shares derived: sum of 2 quarters · filed 2024-05-15 | 35.60K shares derived: sum of 3 quarters · filed 2024-05-15 | 35.60K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-13 | 0.00 shares derived: sum of 3 quarters · filed 2024-03-13 | 46.41K shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-13 | 46.41K shares 10-Q · filed 2023-11-13 | 46.41K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 46.41K shares 10-Q · filed 2023-08-10 | 46.41K shares derived: sum of 3 quarters · filed 2023-08-10 | 47.81K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 46.41K shares 10-Q · filed 2023-05-11 | 46.41K shares derived: sum of 2 quarters · filed 2023-05-11 | 47.81K shares derived: sum of 3 quarters · filed 2023-05-11 | 50.41K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 1.40K shares derived: sum of 2 quarters · filed 2023-03-30 | 4.00K shares derived: sum of 3 quarters · filed 2023-03-30 | 956.60K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 1.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 4.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 956.60K shares 10-Q · filed 2022-11-14 | 1.16M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 2.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 955.20K shares 10-Q · filed 2022-08-10 | 1.16M shares derived: sum of 3 quarters · filed 2022-08-10 | 1.49M shares derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | 952.60K shares 10-Q · filed 2022-05-16 | 1.16M shares derived: sum of 2 quarters · filed 2022-05-16 | 1.49M shares derived: sum of 3 quarters · filed 2022-05-16 | 1.64M shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 203.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 539.09K shares derived: sum of 2 quarters · filed 2022-03-31 | 689.34K shares derived: sum of 3 quarters · filed 2022-03-31 | 1.71M shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 335.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 486.15K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.51M shares 10-Q · filed 2021-11-10 | 1.74M shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 150.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 1.17M shares 10-Q · filed 2021-08-05 | 1.40M shares derived: sum of 3 quarters · filed 2021-08-05 | 1.47M shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 1.02M shares 10-Q · filed 2021-05-06 | 1.25M shares derived: sum of 2 quarters · filed 2021-05-06 | 1.32M shares derived: sum of 3 quarters · filed 2021-05-06 | 1.42M shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 233.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 298.20K shares derived: sum of 2 quarters · filed 2021-03-11 | 403.70K shares derived: sum of 3 quarters · filed 2021-03-11 | 1.21M shares 10-K · filed 2021-03-11 |
| 2020-09-30 | 64.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 170.00K shares derived: sum of 2 quarters · filed 2020-11-05 | 980.83K shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 105.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 916.33K shares 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | 810.83K shares 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | 1.04M shares 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |